Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc., a biopharmaceutical company, engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing two antagonist PD-1 antibodies, such as ENUM 388D4 and ENUM 244C8 for use in treating cancer. The company is also developing antibody drug candidates for various immunomodulatory protein targets, including TIM-3, CD39, and TIGIT. Enumeral Biomedical Holdings, Inc. has collaboration agreements with Merck Sharp & Dohme Corp.; and The University of Texas MD Anderson Cancer Center, as well as a research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded...
200 CambridgePark Drive
Cambridge, MA 02140
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Interim CEO, Interim President, VP of Finance, Chief Accounting Officer, Treasurer & Director
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2016.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings Receives An OTCQB Bid Price Deficiency Notice From OTC Markets
Sep 22 17
On September 19, 2017, Enumeral Biomedical Holdings, Inc. (Company) received an OTCQB Bid Price Deficiency Notice from OTC Markets (Notice). The Notice stated that the Company’s bid price had closed below $0.01 for more than 30 consecutive calendar days and no longer met the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards Section 2.3(2). The Notice also stated that pursuant to Section 4.1 of the OTCQB Standards, the Company is granted a cure period of 90 calendar days during which the minimum closing bid price for the Company’s common stock must be $0.01 or greater for ten consecutive trading days in order to continue trading on the OTCQB marketplace.
Enumeral Biomedical Holdings, Inc. Announces Resignation of Paul J. Sekhri as Director
Sep 5 17
On September 1, 2017, Paul J. Sekhri resigned from the Board of Directors of Enumeral Biomedical Holdings, Inc. Mr. Sekhri’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Enumeral Biomedical Holdings, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2017
Aug 14 17
Enumeral Biomedical Holdings, Inc. announced unaudited consolidated earnings results for the second quarter ended June 30, 2017. For the quarter, the company reported total revenue was $189,741 against $1,498,972 a year ago. Loss from operations was $2,358,221 against $1,487,033 a year ago. Net loss before income taxes was $3,138,594 against $1,347,557 a year ago. Net loss was $3,138,594 against $1,347,557 a year ago. Basic & diluted net loss per common share was $0.02 against $0.03 a year ago. This decrease in revenue is primarily attributable to the company’s license agreement with Pieris Pharmaceuticals and its study agreement with Merck.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 19, 2017